{"id":"placebo-in-combination-with-nivolumab","safety":{"commonSideEffects":[{"rate":"20-40%","effect":"Fatigue"},{"rate":"20-40%","effect":"Diarrhea"},{"rate":"10-30%","effect":"Nausea"},{"rate":"10-30%","effect":"Rash"},{"rate":"5-20%","effect":"Pruritus"},{"rate":"5-20%","effect":"Hypothyroidism"},{"rate":"1-10%","effect":"Hyperthyroidism"},{"rate":"1-10%","effect":"Thyroiditis"},{"rate":"1-10%","effect":"Pneumonitis"},{"rate":"1-10%","effect":"Colitis"}]},"_chembl":{"chemblId":"CHEMBL2108738","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By blocking the PD-1 receptor, nivolumab allows T cells to recognize and attack cancer cells, leading to an immune response against the tumor. This mechanism is particularly effective in treating cancers with high PD-L1 expression.","oneSentence":"Nivolumab is a PD-1 inhibitor that works by blocking the PD-1 receptor on T cells, allowing them to attack cancer cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:51:32.683Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic non-small cell lung cancer, PD-L1 positive"},{"name":"Metastatic renal cell carcinoma"},{"name":"Adenocarcinoma of the bladder"},{"name":"Adenocarcinoma of the esophagus"},{"name":"Adenocarcinoma of the gastroesophageal junction"},{"name":"Adenocarcinoma of the head and neck"},{"name":"Adenocarcinoma of the liver"},{"name":"Adenocarcinoma of the lung"},{"name":"Adenocarcinoma of the pancreas"},{"name":"Adenocarcinoma of the stomach"}]},"trialDetails":[{"nctId":"NCT02194738","phase":"NA","title":"Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-09-26","conditions":"Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIA Lung Cancer AJCC v8","enrollment":8300},{"nctId":"NCT07174947","phase":"PHASE2","title":"SSRI Antidepressant Fluoxetine Improving Immunotherapy Efficacy in Advanced Hepatobiliary Malignancy Patients With Depression and Anxiety","status":"RECRUITING","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2025-10-01","conditions":"Hepatobiliary Malignancy, Fluoxetine, Anxiety Disorders","enrollment":240},{"nctId":"NCT06256328","phase":"PHASE2","title":"A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2024-01-10","conditions":"Gastric Cancer","enrollment":226},{"nctId":"NCT03400332","phase":"PHASE1, PHASE2","title":"A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2018-02-12","conditions":"Cancer, Melanoma","enrollment":281},{"nctId":"NCT04606316","phase":"PHASE1","title":"Surgical Nivolumab And Ipilimumab For Recurrent GBM","status":"ACTIVE_NOT_RECRUITING","sponsor":"Patrick Wen, MD","startDate":"2021-02-01","conditions":"Glioblastoma, GBM, Glioblastoma Multiforme","enrollment":63},{"nctId":"NCT03873402","phase":"PHASE3","title":"A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2019-06-21","conditions":"Renal Cell Carcinoma","enrollment":437},{"nctId":"NCT05337137","phase":"PHASE1, PHASE2","title":"A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2022-05-05","conditions":"Carcinoma, Hepatocellular","enrollment":83},{"nctId":"NCT05034536","phase":"PHASE2","title":"PD-1 Antibody Therapy + Infliximab for Metastatic Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2022-02-07","conditions":"Metastatic Melanoma","enrollment":36},{"nctId":"NCT05111626","phase":"PHASE3","title":"Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amgen","startDate":"2022-03-14","conditions":"Gastric Cancer, Gastroesophageal Junction Adenocarcinoma","enrollment":515},{"nctId":"NCT06059547","phase":"PHASE2","title":"Neoadjuvant Immunotherapy Combined With the Anti-GDF-15 Antibody Visugromab to Treat Muscle Invasive Bladder Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"CatalYm GmbH","startDate":"2023-09-06","conditions":"Bladder Cancer, Adult Solid Tumor","enrollment":31},{"nctId":"NCT07219459","phase":"PHASE2","title":"Visugromab, Nivolumab and a Tyrosine Kinase Inhibitor (TKI) Compared to Double Placebo and a TKI in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure","status":"NOT_YET_RECRUITING","sponsor":"CatalYm GmbH","startDate":"2026-02","conditions":"Unresectable or Metastatic Hepatocellular Carcinoma, Failure of First-Line Treatment That Included an Anti PD-(L)1 Compound, Child-Pugh A Hepatocellular Carcinoma","enrollment":104},{"nctId":"NCT04674683","phase":"PHASE3","title":"Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"HUYABIO International, LLC.","startDate":"2021-08-12","conditions":"Unresectable or Metastatic Melanoma, Progressive Brain Metastasis","enrollment":450},{"nctId":"NCT04149574","phase":"PHASE3","title":"A Study Comparing the Efficacy and Safety of Nivolumab in Combination With Bacillus Calmette-Guerin (BCG) Versus BCG Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC)","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2020-01-15","conditions":"Urinary Bladder Neoplasms","enrollment":13},{"nctId":"NCT03937219","phase":"PHASE3","title":"Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Exelixis","startDate":"2019-06-25","conditions":"Renal Cell Carcinoma","enrollment":855},{"nctId":"NCT02667587","phase":"PHASE3","title":"An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2016-05-09","conditions":"Brain Neoplasms","enrollment":716},{"nctId":"NCT04100018","phase":"PHASE3","title":"A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2020-02-06","conditions":"Prostate Cancer","enrollment":1030},{"nctId":"NCT01844505","phase":"PHASE3","title":"Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2013-06-11","conditions":"Unresectable or Metastatic Melanoma","enrollment":945},{"nctId":"NCT05457959","phase":"PHASE1","title":"Peptide-Pulsed Dendritic Cell Vaccination in Combination With Nivolumab and Ipilimumab for the Treatment of Recurrent and/or Progressive Diffuse Hemispheric Glioma, H3 G34-mutant","status":"WITHDRAWN","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2024-12-01","conditions":"Diffuse Hemispheric Glioma, H3 G34-Mutant","enrollment":""},{"nctId":"NCT04109066","phase":"PHASE3","title":"Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2019-11-18","conditions":"Breast Cancer","enrollment":521},{"nctId":"NCT03138512","phase":"PHASE3","title":"A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove Part of a Kidney","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2017-07-07","conditions":"Carcinoma, Renal Cell","enrollment":1641},{"nctId":"NCT04340193","phase":"PHASE3","title":"A Study of Nivolumab and Ipilimumab and Nivolumab Alone in Combination With Trans-arterial ChemoEmbolization (TACE) in Participants With Intermediate Stage Liver Cancer","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2020-09-14","conditions":"Cancer, Hepatocellular","enrollment":26},{"nctId":"NCT03817125","phase":"PHASE1","title":"Melanoma Checkpoint and Gut Microbiome Alteration With Microbiome Intervention","status":"COMPLETED","sponsor":"Parker Institute for Cancer Immunotherapy","startDate":"2019-01-28","conditions":"Metastatic Melanoma","enrollment":14},{"nctId":"NCT02746796","phase":"PHASE2, PHASE3","title":"Study of ONO-4538 in Gastric Cancer","status":"COMPLETED","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2016-03","conditions":"Gastric Cancer","enrollment":680},{"nctId":"NCT03006705","phase":"PHASE3","title":"Study of Adjuvant ONO-4538 With Resected Gastric Cancer","status":"COMPLETED","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2017-01-31","conditions":"Gastric Cancer","enrollment":800},{"nctId":"NCT04899921","phase":"PHASE2","title":"Troriluzole or Placebo Plus Ipi Plus Nivo in Mel Brain Mets","status":"TERMINATED","sponsor":"Dana-Farber Cancer Institute","startDate":"2021-06-30","conditions":"Melanoma, Metastatic Melanoma","enrollment":1},{"nctId":"NCT05005273","phase":"PHASE2","title":"A Study to Assess BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2022-10-03","conditions":"Non-Small Cell Lung Cancer","enrollment":1},{"nctId":"NCT02823574","phase":"PHASE2","title":"Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2016-11-08","conditions":"Head and Neck Cancer","enrollment":425},{"nctId":"NCT05834413","phase":"NA","title":"Clinical Study on the Prevention of Driver Gene Negative II-IIIa Lung Cancer Recurrence and Metastasis by Staged Chinese Herbal Medicine Combined With Chemotherapy and Immune Checkpoint Inhibitors","status":"NOT_YET_RECRUITING","sponsor":"Shanghai University of Traditional Chinese Medicine","startDate":"2023-05-01","conditions":"Lung Cancer","enrollment":367},{"nctId":"NCT02538666","phase":"PHASE3","title":"An Investigational Immuno-therapy Study of Nivolumab, or Nivolumab in Combination With Ipilimumab, or Placebo in Patients With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based Chemotherapy","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2015-10-13","conditions":"Lung Cancer","enrollment":907},{"nctId":"NCT03980041","phase":"PHASE2","title":"Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)","status":"COMPLETED","sponsor":"Infinity Pharmaceuticals, Inc.","startDate":"2019-09-25","conditions":"Bladder Cancer, Urothelial Carcinoma, Solid Tumor","enrollment":49},{"nctId":"NCT01927419","phase":"PHASE2","title":"Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic Melanoma","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2013-08-23","conditions":"Unresectable Melanoma, Metastatic Melanoma","enrollment":142},{"nctId":"NCT03349710","phase":"PHASE3","title":"Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2017-12-15","conditions":"Squamous Cell Carcinoma of the Head and Neck","enrollment":74},{"nctId":"NCT03329846","phase":"PHASE3","title":"An Investigational Immuno-therapy Study of BMS-986205 Combined With Nivolumab, Compared to Nivolumab by Itself, in Patients With Advanced Melanoma","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2017-11-30","conditions":"Melanoma, Skin Cancer","enrollment":20},{"nctId":"NCT03342352","phase":"PHASE3","title":"Nivolumab Plus Epacadostat in Combination With Chemotherapy Versus the EXTREME Regimen in Squamous Cell Carcinoma of the Head and Neck (CheckMate 9NA/ECHO-310)","status":"WITHDRAWN","sponsor":"Incyte Corporation","startDate":"2017-12-15","conditions":"Head and Neck Cancer","enrollment":""},{"nctId":"NCT03348904","phase":"PHASE3","title":"Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"Incyte Corporation","startDate":"2017-12-27","conditions":"Lung Cancer","enrollment":2}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":42,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["For nivolumab: OPDIVO®"],"phase":"phase_3","status":"active","brandName":"Placebo in combination with nivolumab","genericName":"Placebo in combination with nivolumab","companyName":"HUYABIO International, LLC.","companyId":"huyabio-international-llc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Nivolumab is a PD-1 inhibitor that works by blocking the PD-1 receptor on T cells, allowing them to attack cancer cells. Used for Metastatic non-small cell lung cancer, PD-L1 positive, Metastatic renal cell carcinoma, Adenocarcinoma of the bladder.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}